Denosumab Combined with Alendronate and Nutritional Intervention Improves Bone Metabolism and Density in Postmenopausal Osteoporosis

Abstract

This study aimed to investigate the efficacy of denosumab combined with alendronate and nutritional intervention on bone metabolism and density in postmenopausal patients with osteoporosis. We randomly divided 120 patients with osteoporosis into two groups: an observation group and a control group. The patients in the control group received sodium phosphate and nutrition intervention therapy, while those in the observation group received denosumab combined with sodium phosphate and nutrition intervention therapy. Osteocalcin, procollagen type I N-terminal propeptide, and beta-C-terminal telopeptide levels were lower among patients in the observation group than among those in the control group. The bone densities of the lumbar and femoral neck among patients in the observation group were higher than those among patients in the control group. The visual analog scale scores of patients in the observation group were lower than those of patients in the control group. The fracture rate of patients in the observation group was lower than that of patients in the control group. The adverse reaction rate was similar in both groups. Denosumab combined with alendronate and nutritional intervention is a safe and efficacious approach to improving bone metabolism and bone density in postmenopausal patients, relieving bone pain, and preventing fractures.